Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its price objective cut by equities researchers at JPMorgan Chase & Co. from $10.00 to $7.00 in a research report issued on Monday, Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 141.80% from the stock’s current price.
A number of other analysts also recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Monday, October 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, October 15th. Wall Street Zen raised shares of Recursion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Morgan Stanley set a $5.90 price objective on Recursion Pharmaceuticals in a research note on Friday, October 16th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $7.58.
Get Our Latest Analysis on RXRX
Recursion Pharmaceuticals Trading Down 9.0%
Shares of RXRX stock traded down $0.28 on Monday, hitting $2.90. 14,020,312 shares of the stock were exchanged, compared to its average volume of 19,621,838. The firm has a market capitalization of $1.80 billion, a P/E ratio of -3.23 and a beta of 1.15. The business has a 50-day moving average of $3.78 and a 200 day moving average of $3.49. Recursion Pharmaceuticals has a fifty-two week low of $2.77 and a fifty-two week high of $5.24.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last announced its earnings results on Monday, November 2nd. The company reported ($0.22) EPS for the quarter, hitting the consensus estimate of ($0.22). The business had revenue of $18.55 million during the quarter, compared to analysts’ expectations of $14.81 million. Recursion Pharmaceuticals had a negative net margin of 697.15% and a negative return on equity of 47.85%. During the same quarter in the prior year, the company posted ($0.36) earnings per share. As a group, research analysts forecast that Recursion Pharmaceuticals will post -0.89 EPS for the current fiscal year.
Insider Transactions at Recursion Pharmaceuticals
In other news, CEO Najat Khan sold 22,408 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total transaction of $78,876.16. Following the completion of the transaction, the chief executive officer owned 2,072,890 shares in the company, valued at approximately $7,296,572.80. This represents a 1.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Hershberg sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $5.00, for a total transaction of $125,000.00. Following the sale, the director owned 162,156 shares in the company, valued at $810,780. The trade was a 13.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 167,408 shares of company stock worth $701,276 in the last quarter. Insiders own 6.65% of the company’s stock.
Institutional Trading of Recursion Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC bought a new position in Recursion Pharmaceuticals in the 1st quarter worth about $7,370,000. Jump Financial LLC lifted its holdings in shares of Recursion Pharmaceuticals by 145.0% during the 3rd quarter. Jump Financial LLC now owns 2,497,200 shares of the company’s stock valued at $10,313,000 after buying an additional 1,478,027 shares during the period. First Trust Advisors LP boosted its stake in shares of Recursion Pharmaceuticals by 16.8% in the 3rd quarter. First Trust Advisors LP now owns 3,551,885 shares of the company’s stock worth $14,669,000 after buying an additional 510,056 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Recursion Pharmaceuticals by 18.2% in the 1st quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock worth $7,665,000 after buying an additional 384,486 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Recursion Pharmaceuticals by 29.3% in the first quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company’s stock worth $4,490,000 after acquiring an additional 331,048 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.
Featured Articles
- Five stocks we like better than Recursion Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
